D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a high estimate of $18.00, and a low estimate of $18.00. No alteration is ...
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic competition to battles over getting more drugs to market.
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda Pharmaceuticals: Buy Rating Affirmed Amidst Pipeline Progress and Strategic Expansion
Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...
Hosted on MSN1mon
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
VNDA is developing VGT-1849A, a novel antisense oligonucleotide (ASO)-based JAK2 inhibitor for treating PV and other JAK2-driven hematologic malignancies. VNDA's Zacks Rank & Rising Estimates ...
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.
Morningstar8d
Vanda Pharmaceuticals Inc VNDA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...